Identifying and distinguishing cancer driver genes among thousands of candidate mutations remains a major challenge. Accurate identification of driver genes and driver mutations is critical for advancing cancer research and personalizing treatment based on accurate stratification of patients. Due to inter-tumor genetic heterogeneity, many driver mutations within a gene occur at low frequencies, which make it challenging to distinguish them from non-driver mutations. We have developed a novel method for identifying cancer driver genes. Our approach utilizes multiple complementary types of information, specifically cellular phenotypes, cellular locations, functions, and whole body physiological phenotypes as features. We demonstrate that our method can accurately identify known cancer driver genes and distinguish between their role in different types of cancer. In addition to confirming known driver genes, we identify several novel candidate driver genes. We demonstrate the utility of our method by validating its predictions in nasopharyngeal cancer and colorectal cancer using whole exome and whole genome sequencing.
The natural history of cancer is complex [1] and its genetics highly heterogeneous [2] . 2 Carcinogenesis depends on the accumulation of, and selection for, mutations in genes 3 which are subsequently able to drive, amongst other processes, cell proliferation, 4 immune evasion, genomic instability, and invasiveness. The concept of a cancer driver 5 genes captures the mechanistic requirement for a cell to overcome normal cellular and 6 tissue homeostatic mechanisms and initiate or promote neoplasia and malignancy. The 7 mutations in driver genes are often recessive loss-of-function lesions exemplified by 8 tumor suppressor genes but they can also act dominantly as oncogenes. Determining 9 which mutations or genes act as a bottleneck in the generation of cancer is fraught with 10 problems, as cells carrying one or more driver mutations will also carry a large set of 11 co-selected, "passenger", mutations which constitute most of the normal somatic 12 mutation-load of the expanded cancer cell but which do not directly generate the 13 neoplastic phenotype [3] . 14 Much effort has gone into developing algorithms to identify driver genes and their 15 mutations, most of which are based on the frequency or pattern of mutations in 16 multiple tumors and their predicted pathogenicity. The goal of identifying cancer 17 drivers may be achieved at the level of gene, protein or pathways, and multiple 18 approaches have been attempted to date [4] . There is no gold standard against which 19 the success of an algorithm can be measured, although the Cancer Gene Census 20 approaches a "gold standard" most closely with an expert-curated dataset of 21 cancer-associated genes and mutations [5] . 22 Investigators have increasingly relied on taking a consensus of multiple methods and, 23 where possible, attempted to experimentally verify driver gene status in cellular or 24 whole organism systems [6] . Many thousands of tumors have now been sequenced in 25 very large-scale studies of multiple cancer types, and several hundred genes and 26 mutations have been identified as "drivers" -with varying support from experimental 27 and genetic studies [6] . These methods, however, do not work well for low-intermediate 28 and rare driver genes which may bear up to 20% of driver mutations [7] , and the 29 identification of drivers in specific cancers and sub-types of tumor remains difficult, 30 often because of small numbers of tumors available. 31 An alternative strategy to sequence-based ratiometric type mutation frequency based 32 approaches is to identify a "fingerprint" for cancer driver genes from a range of 33 biological and molecular data and to use this as part of a classifier that can filter 34 sequence information. For example, it is possible to utilize gene annotations and 35 biological properties of known driver genes in a machine learning approach and identify 36 some novel driver gene candidates [8] . Here, we report a novel method in which we use 37 a combination of direct functional evidence, obtained through cell growth assays after 38 introducing a specific mutation into cells, and related functional characteristics available 39 from basic biological experiments and recorded in model organism databases and 40 databases characterizing protein functions to build a classifier that determined whether 41 a gene may likely become a driver gene.
Uniprot [12] as well as several model organism databases.
50
In these databases, ontologies are used for characterizing phenotypes, gene functions 51 and cellular locations. Over the past decades, a tightly integrated system of ontologies 52 has been developed that interlinks the knowledge about basic biological phenomena 53 through the use of logical axioms [13] . Exploring the information in this system of 54 ontologies can enable novel types of analysis [14] and the background knowledge in the 55 ontologies has the potential to significantly improve biomedical data analysis [15] . 56 We have developed a method that uses biological background knowledge about the 57 relation between genes or variants and their phenotypes, either on the cellular or whole 58 body organism level, as well as gene functions and cellular locations, to predict driver 59 genes and mutations. Our approach relies on neuro-symbolic deep learning to 60 systematically encode for background knowledge about basic biological processes and 61 phenomena. Specifically, we generate "embeddings" for gene functions and 62 gene-phenotypes associations and use a deep artificial neural network trained on known 63 driver genes -and the knowledge about how they relate to functions and phenotypes -64 to discover new cancer drivers. We demonstrate that our method can predict novel 65 driver genes by analyzing three cohorts of different cancers, and we demonstrate that 66 the predicted driver genes have a significantly higher somatic mutation frequency, are 67 significantly more likely to be functionally related to known drivers, and have a 68 significantly higher rate of pathogenic somatic variants. We make our method and 69 prediction results freely available from 70 https://github.com/bio-ontology-research-group/predCAN.
71

Results
72
Representation learning 73
Our aim is to utilize information about the functions and phenotypes associated with 74 genes to identify cancer driver genes and, subsequently, driver mutations. This 75 information is represented using biomedical ontologies, and these ontologies also contain 76 a substantial amount of background information about the relations between biological 77 functions, processes, and phenotypes in the form of logical axioms and natural language 78 definitions [14] . The information in ontologies is utilized by human experts to 79 understand and interpret the implications of an association with a class in an ontology, 80 and a comprehensive interpretation of these associations relies on comprehension and 81 utilization of biological background knowledge. 82 We use three types of information associated with genes: cellular phenotypes 83 observed in large-scale microscopy studies and recorded using the Cellular Microscopy 84 Phenotype Ontology (CMPO) [16] ; gene functions and cellular locations recorded by 85 Uniprot [12] and encoded using the Gene Ontology (GO) [17] ; and phenotypes of 86 knockout mouse models provided by the Mouse Genome Informatics (MGI) 87 database [10] and encoded using the Mammalian Phenotype Ontology (MP) [18] .
88
Each of these ontologies contains logical axioms that define and restrict the classes 89 and provide background knowledge about the domain of functions, cellular phenotypes, 90 or physiological phenotypes [18] . Figure 1 shows an example of how the ontologies 91 overlap in their content and how classes in phenotype ontologies are defined or 92 constrained using classes from other ontologies. 93 We developed a method that combines the associations of genes and ontology classes 94 with the background information in ontologies (both the formal logical content and the 95 informal natural language components) in a single feature vectors that represents each formally represented knowledge [19] ; as a result, we obtain an embedding -a function 99 from an ontology and its associated entities into an n-dimensional vector space -which 100 generates feature vectors that encode for known associations of genes and their 101 functions or phenotypes as well as the ontologies' background knowledge.
102
Because different genes are covered differently in the databases we use, we generate 103 five different representations for gene. The first three representations are based on 104 annotating the genes using the ontologies that we used one at a time, combining the 105 ontology-based annotations and the ontology axioms within a single representation so 106 that the background knowledge within the ontologies becomes accessible. However, we 107 can only generate the feature vectors if there are ontology-based annotations for a gene 108 and therefore we obtain a different number of feature vectors when utilizing different 109 ontologies. To determine if we can predict better, we combine the embeddings generated 110 from each gene if all three features are available and evaluate the performance on the 111 intersection of genes for which features in all three ontologies can be generated. Finally, 112 we determined if it is possible to "impute" missing information by utilizing ontology 113 axioms. For this purpose, we first merge the three ontology (CMPO, GO, MP) into a 114 single ontology model and generate the embeddings for each gene which is annotated to 115 information in at least one of the three ontologies we use. We use the generated feature 116 vectors as input to a deep neural network that we train to predict cancer driver genes 117 and distinguish between 20 cancer types for which a gene can be considered a driver. We first test how well each type of feature predicts cancer driver genes separately. For 121 this purpose, we construct a machine-learning model to classify genes into driver genes 122 for particular cancer types; we distinguish between 20 different types of cancer (see 123 Supplementary Table 1 ) taken from the IntoGen database [20] . The machine learning 124 model we use is illustrated in Supplementary Figure 1 . We evaluate the results using Table 1 . We then 126 combine the features and the ontologies that contain background knowledge about the 127 respective domains; when adding ontologies containing background knowledge about the 128 cellular phenotypes and functions of genes we achieve a significant improvement of 129 prediction results compared to predicting based on individual features (see Table 1 , 130 Figure 2 for ROC curves and Figure 3 for the precision-recall curves). As our method 131 can accurately predict cancer driver genes, we apply our model to all human genes (i.e., 132 all negatives in our dataset) and predict 112 novel candidate driver genes for 20 133 different cancer types (Supplementary Tables 2 and 3 ).
134 Table 1 . ANN performance in identification driver/non-driver genes of different cancer types. We first determine the performance using each ontology-based feature separately (using each ontology individually as background knowledge), and then determine the performance only on genes for which we have all three ontology-based features (Intersection); in the "Intersection" case, embedding vectors are concatenated. Finally, we determine the performance on genes for which we have at least one feature (Union); in the latter case, ontologies are merged.
Experiments Driver genes will generally accumulate more mutations than other genes in cancer 137 tissue [21] . We use the complete list of genes in the IntoGen database and separate 138 them into three groups: genes listed as confirmed cancer drivers, genes predicted as 139 cancer drivers for one or more tumor types by our method, and genes not predicted or 140 known as cancer driver genes. We use the recorded somatic mutations in the IntoGen 141 database to determine the somatic mutation frequency for each human gene (i.e., the 142 number of mutations divided by the length of the gene). We find that candidate driver 143 genes predicted by our method have a significantly higher somatic mutation frequency 144 than non-driver genes (p = 0.560 × 10 −12 , one-tail t-test). 145 We also evaluate our predictions on a set of 26 tumor samples for nasopharyngeal 146 cancer obtained from patients at King Abdulaziz University Hospital in Jeddah, Saudi 147 Arabia, for which we have performed whole exome sequencing. Nasopharyngeal cancer 148 is a type of squamous cell carcinoma of the head and neck for which we identify seven 149 novel candidate driver genes (see Supplementary Table 3 ). In this set of samples, the 150 predicted driver genes have a significantly higher somatic mutation frequency compared 151 to non-driver genes (p = 0.115 × 10 −5 , one-tail t-test).
152
Moreover, we applied the same analysis to 114 tumor/normal samples for colorectal 153 adenocarcinoma obtained from the University of Birmingham Hospital in UK. We 154 identified 12 candidate driver genes for colorectal adenocarcinoma. Among the 114 155 samples, the predicted driver genes have a significantly higher somatic mutation 156 frequency compared to non-driver genes (p = 0.204 × 10 −3 , one-tail t-test).
Predicted cancer driver genes are functionally related to known 158 cancer drivers 159 Cancer drivers are known to form functional modules on interaction networks [22] . We 160 use the STRING interaction network [23] to determine whether the genes we predict are 161 functionally related to known driver genes. STRING contains several types of 162 interaction between genes and proteins, including physical interactions, genetic 163 interactions, co-location, and co-expression. 164 We find that 24 out of the 112 candidate driver genes have a direct interaction with 165 a known driver gene within their respective cancer type. In a random distribution (see 166 Methods), on average six genes are connected to a known driver gene, demonstrating 167 that our predicted drivers are significantly more likely to be functionally related to a 168 known driver gene (p = 0.731 × 10 −7 , one-tail t-test).
169
Predicted driver genes are enriched for pathogenic variants 170 Our method can also be used to detect driver variants in tumor samples. We use seven 171 different methods for predicting deleteriousness of variants and compare the 172 pathogenicity scores of variants in candidate driver genes to known and non-driver genes 173 in nasopharyngeal carcinoma exomes. Variants in the seven predicted driver genes for 174 head and neck squamous cell carcinoma generally are scored more pathogenic than 175 variants non-driver genes by most prediction tools (SIFT: p = 0.324 × 10 −5 , PolyPhen-2: 176 p = 0.098, MutationAssessor: p = 0.378 × 10 −6 , MutationTaster: p = 0.372 × 10 −10 , 177 CADD: p = 0.818, VEST3: p = 0.169 × 10 −12 and FATHMM: p = 0.912 × 10 −14 ;
178 Mann-Whitney U test). 179 We apply the same test on the cohort of colorectal adenocarcinoma samples. The set 180 of variants in the predicted driver genes for colorectal adenocarcinoma (see 181 Supplementary Table 5 ) are scored as significantly more pathogenic than variants in 182 non-driver genes by most pathogenicity prediction methods (SIFT: p = 0.631 × 10 −6 , 183 PolyPhen-2: p = 0.725 × 10 −8 , MutationAssessor: p = 0.405 × 10 −2 , MutationTaster: 184 p = 0.917, CADD: p = 0.811, VEST3: p = 0.040 and FATHMM: p = 0.648 × 10 −8 ;
185
Mann-Whitney U test). 186 We can also use these methods to suggest candidate driver mutations in the cohorts 187 as well as individual patients. Supplementary Tables 4 and 5 lists all rare variants in 188 predicted driver genes in the predicted driver genes for nasopharyngeal carcinoma and 189 colorectal cancer. For example, TGM3 has previously been studied as candidate driver 190 in carcinomas of the head and neck [24] , and we identify rs200294064 in TGM3 as 191 pathogenic candidate driver mutation. 193 Our method can predict cancer driver genes using only public background knowledge 194 about gene functions, cellular and organism phenotypes. The key novelty of our 195 algorithm is the ability to encode biological background knowledge in ontologies [15] , 196 and therefore exploit inter-ontology links in the form of axioms; the predictive 197 performance of our method is best when combining different -yet related -ontologies. 198 While many of the axioms that relate classes in different ontologies have been created to 199 support ontology development and maintenance, we show that ontologies in the 200 biomedical domain now form a comprehensive web of biological background knowledge 201 that can -when exploited through appropriate learning algorithms -significantly connection between different ontologies is the Relation Ontology [25] which is central to 204 ontologies that make up the OBO Foundry [13] . 205 Through the application of our method we identify novel driver genes by 206 systematically analyzing public knowledge on multiple levels of granularity. We use 207 sequencing data -both public and patient-derived -as validation. This strategy is the 208 opposite of most computational and experimental approaches in which molecular data is 209 used as feature and additional functional evidence collected after predictions [6, 26] . Our 210 approach can also identify consensus cancer driver genes as we found 8 out of the 112 211 have been listed in the current COSMIC of confirmed consensus cancer driver genes [27] 212 (see Supplementary Table 6 ). Moreover, we found 12 out of the 26 rare variants within 213 the predicted driver genes for both nasopharyngeal and colorectal cohorts mentioned in 214 International Cancer Genome Consortium (ICGC) data [28] (see Supplementary Table 215 7). One of the key novelties in our approach is the use of phenotype data -both on the 216 cellular and whole organism levels of granularity -to characterize cancer driver genes. 217
192
Discussion
Materials and methods
218
Data sources and ontologies 219 We performed all our experiments on a set of driver/non-driver genes from the 220 Mutational Cancer Drivers Database (intOGen) [20] and Cellular Phenotype Database 221 (CPD) [11] 230 We mapped all gene identifiers to Entrez gene identifiers and used the mapping file 231 between Ensembl gene identifiers and Entrez genes provided by the Cellular Phenotype 232 Database (CPD) [11] ; we converted UniProt identifiers of proteins in the GO 233 annotations to Entrez gene identifiers using the UniProt mapping tool provided on the 234 UniProt website [12] ; and for assigning phenotypes to genes we use mouse orthologs of 235 human genes and assign the phenotypes associated with loss-of-function mutations in 236 mice in the MGI database [10] to the human genes. 237 We started with 20,352 human genes of which 13,116 are annotated using the 238 Cellular Microscopy Phenotype Ontology (CMPO) [16] , 17,591 are annotated using the 239 Gene ontology (GO) [17] , and 7,884 are annotated with the Mammalian Phenotype 240 Ontology (MP) [18] .
241
Generating of ontology annotation-based features 242 We used the OPA2Vec approach [19] to generate "embeddings" representing genes based 243 on the different ontologies and the annotations of the genes with the ontologies. An
Supervised training 250
We investigated the performance of a machine learning based classification algorithm in 251 identifying new driver genes. In our experiments, we used known driver genes within 20 252 different cancer types as the positive set, and randomly selected an equal number of the 253 non-driver genes as the negative set.
254
For the training and testing, we performed stratified 10-fold cross-validation. We 255 performed a limited grid search for optimal sets of hyperparameters of the neural 256 network using the Hyperas system [29] . We used a Rectified Linear Unit as an 257 activation function [30] for the hidden layers and a sigmoid function as the activation 258 function for the output layer; we used cross entropy as loss function in training, and 259 Rmsprop [31] to optimize the neural networks parameters in training. For nasopharyngeal cancer samples we used GATK with Mutect2 [32] for sample 278 preparation and generating somatic short variant calling files following tumor-only 279 mode. For colorectal carcinoma, Strelka [33] was used with tumor/normal pairs to 280 detect somatic mutations. We filter all variants that do not lie within a coding region in 281 both cohorts. 282 We annotate the resulting VCF files with Annovar [34] to extract variant-related 283 information such as the gene(s) in which a variant lies and the start and end position of 284 the gene, and the different pathogenicity scores.
285
Detection of network modules 286 To determine a neutral distribution of the number of connections between cancer driver 287 genes within STRING empirically, we repeatedly sample 112 random nodes from the 288 STRING interaction network [23] and calculate the number of genes which are 289 connected to known cancer driver genes. We repeat this process 10,000 times. 
